Biology and genetics of oculocutaneous albinism and vitiligo - Common pigmentation disorders in southern Africa

South African Medical Journal

Volumn 103, Issue SUPPL. 1, 2013, Pages 984-988

  Manga, P ^a   Kerr, R ^b   Ramsay, M ^b   Kromberg, J G R ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Albinism; Festschrift; Human genetics; Skin pigment; Trefor Jenkins

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; INTERLEUKIN 6; INTERLEUKIN 8; MELANIN; MELANOCORTIN 1 RECEPTOR; NITISINONE; TYROSINE;

AFRICA; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVITY; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; NONHUMAN; OCULOCUTANEOUS ALBINISM; OXIDATIVE STRESS; PIGMENT EPITHELIUM; PREVALENCE; RHEUMATOID ARTHRITIS; VISUAL ACUITY; VITILIGO;

AFRICA; ALBINISM, OCULOCUTANEOUS; HERMANSKI-PUDLAK SYNDROME; HUMANS; MEMBRANE GLYCOPROTEINS; OXIDATIVE STRESS; OXIDOREDUCTASES; VITILIGO;

EID: 84889667109     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/SAMJ.7046     Document Type: Article

References (49)

1. Gilchrest BA. Skin aging and photoaging: An overview. J Am Acad Dermatol 1989; 21(3 Pt 2): 610-613. [http://dx. doi. org/10. 1016/S0190-9622(89)70227-9].
2. Hatchome N, Aiba S, Kato T, Torinuki W, Tagami H. Possible functional impairment of Langerhans' cells in vitiliginous skin. Reduced ability to elicit dinitrochlorobenzene contact sensitivity reaction and decreased stimulatory effect in the allogeneic mixed skin cell lymphocyte culture reaction. Arch Dermatol 1987; 123(1): 51-54. [http://dx. doi. org/10. 1001/archderm. 1987. 01660250057017].
3. Porter J, Beuf AH, Lerner A, Nordlund J. Response to cosmetic disfigurement: Patients with vitiligo. Cutis 1987; 39(6): 493-494.
4. Kawakami A, Fisher DE. Key discoveries in melanocyte development. J Invest Dermatol 2011; 131(E1): E2-E4. [http://dx. doi. org/10. 1038/skinbio. 2011. 2].
5. Tassabehji M, Newton VE, Read AP. Waardenburg syndrome type 2 caused by mutations in the human microphthalmia (MITF) gene. Nat Genet 1994; 8(3): 251-255. [http://dx. doi. org/10. 1038/ng1194-251].
6. Wei ML. Hermansky-Pudlak syndrome: A disease of protein trafficking and organelle function. Pigment Cell Res 2006; 19(1): 19-42. [http://dx. doi. org/10. 1111/j. 1600-0749. 2005. 00289. x].
7. Ebanks JP, Koshoffer A, Wickett RR, et al. Epidermal keratinocytes from light vs. dark skin exhibit differential degradation of melanosomes. J Invest Dermatol 2011; 131(6): 1226-1233. [http://dx. doi. org/10. 1038/jid. 2011. 22].
8. Thong H-Y, Jee S-H, Sun C-C, Boissy RE. The pattern and mechanism of melanosome distribution in keratinocytes of human skin as one determining factor of skin colour. Br J Dermatol 2003; 149: 498-505.
9. Nan H, Kraft P, Qureshi AA, et al. Genome-wide association study of tanning phenotype in a population of European ancestry. J Invest Dermatol 2009; 129(9): 2250-2257. [http://dx. doi. org/10. 1038/jid. 2009. 62].
10. Rees JL. Genetics of hair and skin color. Annu Rev Genet 2003; 37: 67-90.
11. Sturm RA, Frudakis TN. Eye colour: Portals into pigmentation genes and ancestry. Trends Genet 2004; 20(8): 327-332. [http://dx. doi. org/10. 1016/j. tig. 2004. 06. 010].
12. Oetting WS, King RA. Molecular basis of type I (tyrosinase-related) oculocutaneous albinism: Mutations and polymorphisms of the human tyrosinase gene. Hum Mutat 1993; 2(1): 1-6. [http://dx. doi. org/10. 1002/humu. 1380020102].
13. Lee ST, Nicholls RD, Bundey S, Laxova R, Musarella M, Spritz RA. Mutations of the P gene in oculocutaneous albinism, ocular albinism, and Prader-Willi syndrome plus albinism. N Engl J Med 1994; 330(8): 529-534. [http://dx. doi. org/10. 1056/NEJM199402243300803].
14. Manga P, Kromberg JG, Box NF, Sturm RA, Jenkins T, Ramsay M. Rufous oculocutaneous albinism in southern African blacks is caused by mutations in the TYRP1 gene. Am J Hum Genet 1997; 61(5): 1095-1101. [http://dx. doi. org/10. 1086/301603].
15. Newton JM, Cohen-Barak O, Hagiwara N, et al. Mutations in the human orthologue of the mouse underwhite gene (uw) underlie a new form of oculocutaneous albinism, OCA4. Am J Hum Genet 2001; 69(5): 981-988. [http://dx. doi. org/10. 1086/324340].
16. Kromberg JG, Zwane EM, Jenkins T. The response of black mothers to the birth of an albino infant. Am J Dis Child 1987; 141(8): 911-916.
17. Kromberg JG, Jenkins T. Albinism in the South African Negro. III. Genetic counselling issues. J Biosoc Sci 1984; 16(1): 99-108. [http://dx. doi. org/10. 1017/S0021932000014838].
18. Ezeilo BN. Psychological aspects of albinism: An exploratory study with Nigerian (Igbo) albino subjects. Soc Sci Med 1989; 29(9): 1129-1131. [http://dx. doi. org/10. 1016/0277-9536(89)90026-9].
19. Garrod AE. The Croonian lectures on inborn errors of metabolism. Lancet 1908; 172(4427): 73. [http://dx. doi. org/10. 1016/S0140-6736(01)78482-6].
20. Stevens G, van Beukering J, Jenkins T, Ramsay M. An intragenic deletion of the P gene is the common mutation causing tyrosinase-positive oculocutaneous albinism in southern African Negroids. Am J Hum Genet 1995; 56(3): 586-591.
21. Kromberg JG, Jenkins T. Prevalence of albinism in the South African negro. S Afr Med J 1982; 61(11): 383-386.
22. Witkop CJ, Jr. Inherited disorders of pigmentation. Clin Dermatol 1985; 3(1): 70-134.
23. Onojafe IF, Adams DR, Simeonov DR, et al. Nitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous albinism. J Clin Invest 2011; 121(10): 3914-3923. [http://dx. doi. org/10. 1172/JCI59372].
24. Vanclooster A, Devlieger R, Meersseman W, et al. Pregnancy during nitisinone treatment for tyrosinaemia type I: First human experience. JIMD Rep 2012; 5: 27-33. [http://dx. doi. org/10. 1007/8904_2011_88].
25. Gardner JM, Nakatsu Y, Gondo Y, et al. The mouse pink-eyed dilution gene: Association with human Prader-Willi and Angelman syndromes. Science 1992; 257(5073): 1121-1124. [http://dx. doi. org/10. 1126/science. 257. 5073. 1121].
26. Ramsay M, Colman MA, Stevens G, et al. The tyrosinase-positive oculocutaneous albinism locus maps to chromosome 15q11. 2-q12. Am J Hum Genet 1992; 51(4): 879-884.
27. Kerr R, Stevens G, Manga P, et al. Identification of P gene mutations in individuals with oculocutaneous albinism in sub-Saharan Africa. Hum Mutat 2000; 15(2): 166-172. [http://dx. doi. org/10. 1002/(SICI)1098-1004(200002)15: 2<166:: AID-HUMU5>3. 3. CO; 2-Q].
28. King RA, Creel D, Cervenka J, Okoro AN, Witkop CJ. Albinism in Nigeria with delineation of new recessive oculocutaneous type. Clin Genet 1980; 17(4): 259-270. [http://dx. doi. org/10. 1111/j. 1399-0004. 1980. tb00145. x].
29. Manga P, Kromberg JG, Turner A, Jenkins T, Ramsay M. In southern Africa, brown oculocutaneous albinism (BOCA) maps to the OCA2 locus on chromosome 15q: P-gene mutations identified. Am J Hum Genet. 2001; 68(3): 782-787. [http://dx. doi. org/10. 1086/318800].
30. Kromberg JG, Castle DJ, Zwane EM, et al. Red or rufous albinism in southern Africa. Ophthalmic Paediatr Genet 1990; 11(3): 229-235. [http://dx. doi. org/10. 3109/13816819009020984].
31. Witkop CJJ, Quevedo WCJ, Fitzpatrick TB. Albinism and other disorders of pigment metabolism. In: Stanbury J, Wyngerden JB, Fredrickson DS, Goldstein JL, Brown MS, eds. The metabolic basis of inherited disease. New York: McGraw Hill, 1983: 301-346.
32. Kidson SH, Richards PD, Rawoot F, Kromberg JG. An ultrastructural study of melanocytes and melanosomes in the skin and hair bulbs of rufous albinos. Pigment Cell Res 1993; 6(4 Pt 1): 209-214. [http://dx. doi. org/10. 1111/j. 1600-0749. 1993. tb00604. x].
33. Toyofuku K, Wada I, Valencia JC, Kushimoto T, Ferrans VJ, Hearing VJ. Oculocutaneous albinism types 1 and 3 are ER retention diseases: Mutation of tyrosinase or Tyrp1 can affect the processing of both mutant and wild-type proteins. Faseb J 2001; 15(12): 2149-2161. [http://dx. doi. org/10. 1096/fj. 01-0216com].
34. Manga P, Sato K, Ye L, Beermann F, Lamoreux ML, Orlow SJ. Mutational analysis of the modulation of tyrosinase by tyrosinase-related proteins 1 and 2 in vitro. Pigment Cell Res 2000; 13(5): 364-374. [http://dx. doi. org/10. 1034/j. 1600-0749. 2000. 130510. x].
35. Manga P, Orlow SJ. Informed reasoning: Repositioning of nitisinone to treat oculocutaneous albinism. J Clin Invest 2011; 121(10): 3828-3831. [http://dx. doi. org/10. 1172/JCI59763].
36. Boissy R. Extracutaneous melanocytes. In: Nordlund J, Boissy R, Hearing V, King R, Ortonne J, eds. The Pigmentary System Physiology and Pathophysiology. New York: Oxford University Press, 1998: 59-73.
37. Parsad D, Dogra S, Kanwar AJ. Quality of life in patients with vitiligo. Health Qual Life Outcomes 2003; 1: 58. [http://dx. doi. org/10. 1186/1477-7525-1-58].
38. Nancy AL, Yehuda S. Prediction and prevention of autoimmune skin disorders. Arch Dermatol Res 2009; 301(1): 57-64. [http://dx. doi. org/10. 1007/s00403-008-0889-3].
39. Taieb A. Vitiligo as an inflammatory skin disorder: A therapeutic perspective. Pigment Cell Melanoma Res 2012; 25(1): 9-13. [http://dx. doi. org/10. 1111/j. 1755-148X. 2011. 00939. x].
40. Jin Y, Birlea SA, Fain PR, et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med 2010; 362(18): 1686-1697. [http://dx. doi. org/10. 1056/NEJMoa0908547].
41. Halder RM, Chappell JL. Vitiligo update. Semin Cutan Med Surg 2009; 28(2): 86-92. [http://dx. doi. org/10. 1016/j. sder. 2009. 04. 008].
42. Jin Y, Birlea SA, Fain PR, et al. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet 2012; 44(676-680). [http://dx. doi. org/10. 1038/ng. 2272].
43. Yildirim M, Baysal V, Inaloz HS, Kesici D, Delibas N. The role of oxidants and antioxidants in generalized vitiligo. J Dermatol 2003; 30(2): 104-108.
44. Dammak I, Boudaya S, Ben Abdallah F, Turki H, Attia H, Hentati B. Antioxidant enzymes and lipid peroxidation at the tissue level in patients with stable and active vitiligo. Int J Dermatol 2009; 48(5): 476-480. [http://dx. doi. org/10. 1111/j. 1365-4632. 2009. 03998. x].
45. Le Poole C, Boissy RE. Vitiligo. Semin Cutan Med Surg 1997; 16(1): 3-14.
46. Malhotra JD, Kaufman RJ. The endoplasmic reticulum and the unfolded protein response. Semin Cell Dev Biol 2007; 18(6): 716-731. [http://dx. doi. org/10. 1016/j. semcdb. 2007. 09. 003].
47. Toosi S, Orlow SJ, Manga P. Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol 2012; 132(11): 2601-2609. [http://dx. doi. org/10. 1038/jid. 2012. 181].
48. Lipson KL, Fonseca SG, Ishigaki S, et al. Regulation of insulin biosynthesis in pancreatic beta cells by an endoplasmic reticulum-resident protein kinase IRE1. Cell Metab 2006; 4(3): 245-254. [http://dx. doi. org/10. 1016/j. cmet. 2006. 07. 007].
49. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther 2011; 11(12): 1663-1668. [http://dx. doi. org/10. 1517/14712598. 2011. 627850].